NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Saw nearly the same message over on Peregrine before Bavituximab's total failure. Their CEO was also previously named "Worst CEO of the Year" by AF. But their common shareholders actually got to reap the rewards a little later with a fully functional CDMO.

On another note, I've been thinking about the silly notion of abandoning PFS for OS in immunotherapy trials. There are plenty of methods today to discern true tumor progression vs. pseudo. Desired outcomes should reflect a good primary read on Durable PFS not OS. And, especially with GBM where the brain tumors nearly always returns.